JD.com’s CTO Mr. Zhang Chen and VP Dr. Li Kefeng to Give CES Asia 2017 Keynote
17.5.2017 10:00:00 EEST | Business Wire | Press release
The Consumer Technology Association (CTA) announced today that top executives from JD.com, China’s largest retailer (both online and offline), will deliver a keynote address at the upcoming CES Asia 2017 in Shanghai. JD.com’s chief technology officer (CTO) Mr. Zhang Chen, and vice president, Dr. Li Kefeng, will take the keynote stage at 4 PM, Thursday, June 8, in the Kerry Hotel, Level 3, Shanghai Ballrooms 2-3.
Mr. Zhang and Dr. Li will discuss how JD.com is leveraging artificial intelligence (AI), smart devices, augmented/virtual reality and big data to make e-commerce smarter and more interconnected. The two executives will share the company’s vision for making e-commerce easier and more efficient, as well as its ability to provide customers a better user experience. As part of the presentation, they will unveil the company’s new initiatives and programs for the future.
“JD.com is a pioneer in the e-commerce landscape in China. JD.com has succeeded in extending its innovative vision globally, and is now one of the biggest and fastest-growing companies in the world,” said Gary Shapiro, president and CEO, CTA. “It is my pleasure to welcome Mr. Zhang Chen and Dr. Li Kefeng to the CES Asia keynote stage. I look forward to their discussion of how integrating groundbreaking technologies can enhance consumer experiences and change our lives for the better.”
Mr. Zhang Chen is the CTO of JD.com, in charge of driving research and development growth in big data and cloud computing, as well as technical support for the daily operation of JD Mall. Mr. Zhang has more than 20 years of experience in software development and management. Prior to joining JD.com, he worked at Yahoo for 18 years and at one point was responsible for the development of Yahoo Messenger. More recently he worked at DEC and Oracle Corporation as head of technology. In addition, he headed the global R&D center at Yahoo Beijing. He holds a Master’s Degree in Computer Science from Indiana University Bloomington.
As Vice President at JD.com, Dr. Li Kefeng is responsible for the business lines of mobile products, e-commerce open platform, smart devices and AR/VR. He leads the team in strategic planning, product innovation and ecosystem development. He is focused on creating a next generation e-commerce shopping experience by leveraging cutting-edge technologies. Before joining JD.com, Dr. Li worked for Samsung, Baidu and Ping An Insurance (Group) of China, with senior management positions at each. Dr. Li holds a Ph.D. Degree from Beihang University.
More than 400 companies are already slated to exhibit including 3M, Audio-Technica, Baidu, BMW, BYD, Carl Zeiss, Changhong Electric, China Mobile, Continental, Digital China, DJI, Dynaudio, Fossil/Misfit, Garmin, Gibson Brands, Goertek, Haier, Harman, Hisense, Honda, Huawei, Hyundai, JD.com, Konka Group, Mercedes-Benz, Monster, NavInfo, NEVS, Onkyo, OnStar, OtterBox, Pioneer, PPTV, Samsung, Scosche, Segway, Suning, Tencent, United States Postal Service, UPS, Valeo, Volvo, Voxx, Wacom and Yuneec. Ultimately, CES Asia 2017 is expected to draw more than 30,000 attendees and more than 1,100 global media to cover the latest tech innovation across 19 product categories, including major growth areas such as drones, the Internet of Things (IoT) and virtual reality.
For more information on how to attend or exhibit, visit CESAsia.com. All CES Asia industry affiliated attendees may access the keynotes with a valid show badge.
Note to Editors: Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351.
About CES Asia:
Owned and produced by the Consumer Technology Association (CTA)TM and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About Consumer Technology Association:
Consumer Technology Association (CTA) is the trade association representing the $292 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.
UPCOMING EVENTS
-
CES Asia 2017 –
Register
June 7-9, Shanghai, China
-
CEO Summit
June 21-24, Amalfi Coast, Italy
-
Innovate! and Celebrate
October 9-11, San Francisco, CA
-
CES 2018
January 9-12, Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005405/en/
Contact information
Consumer Technology Association
Sarah Brown, 703-907-4326
sbrown@CTA.tech
www.CESAsia.com
or
Bernice
Morquette, 703-907-7651
bmorquette@CTA.tech
www.CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
